ELTP — ELITE PHARMACEUTICALS INC /NV/

OTC · Health Care · Pharmaceuticals · CIK 1053369 ·
Last close
$0.29
Market Cap
$310.75M
52W High
$0.45
52W Low
$0.27
ADV30
677,204
Next earnings
2026-11-12
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 40,748,067 20,772,157 11,033,800 18,461,188 138,289,840 29,797,800 39,406,865
Dec 2025 31,589,251 12,953,175 9,012,943 18,593,806 126,412,637 21,094,904 46,098,554
Sep 2025 36,321,704 14,073,033 8,213,746 13,702,407 117,247,811 26,617,346 55,662,843
Jun 2025 40,211,097 27,225,970 21,699,707 -5,884,715 111,339,370 21,737,797 63,656,727

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$23,748,094
Investing CF
$-925,626
Financing CF
$-4,322,309
CapEx
$-925,626
Dividends Paid
Buybacks
EPS Diluted TTM
$0.00
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-75,831,240
Inventory
$21,259,898
Receivables
$59,715,676
ST Investments
EBIT TTM
$57,211,148
Pretax Income TTM
$56,814,484
Interest Exp TTM
$396,664
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$141,014,304
EBITDA
$37,310,520
Free Cash Flow
$23,001,620
Enterprise Value
$278,032,576
Total Cash
$38,940,136
Total Debt
$5,572,569
Shares Out
1,077,136,442
Trailing EPS
$0.05
Book Value
$0.10
ROE
74.3%
ROA
17.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 148,870,119 49,960,196 44,872,686 138,289,840 39,406,865 23,748,094
Mar 2025 84,043,929 21,203,894 -4,314,659 96,387,477 42,872,448 7,455,639
Mar 2024 56,625,128 10,788,769 20,108,631 83,653,536 26,070,718 -3,235,115
Mar 2023 34,155,114 3,968,809 3,561,846 40,896,018 11,935,758 3,338,704

Peers — same industry

TickerNameMarket CapLastDaily %
RNAC Cartesian Therapeutics, Inc. $304.37M $10.06
IFRX InflaRx N.V. $302.10M $2.05
VNDA Vanda Pharmaceuticals Inc. $322.27M $5.33
CYDY CytoDyn Inc. $297.23M $0.22
TTRX Turn Therapeutics Inc. $293.96M $9.68

News headlines (Yahoo Finance, 1h cache)

Elite Pharmaceuticals Inc (ELTP) (Q1 2027) Earnings Call Highlights: Steady Revenue and ...
2026-08-18 01:08 · Yahoo
Elite Pharmaceuticals Q1 Earnings Call Highlights
2026-08-14 19:02 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
2026-08-13 20:11 · Yahoo
Elite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call Highlights: Record Revenue Growth and ...
2026-07-01 01:00 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
2026-06-29 20:29 · Yahoo
Possible Generic Drug Tariffs and 2 Microcaps
2026-07-31 06:08 · Yahoo
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
2026-07-15 15:22 · Yahoo
Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y
2026-08-19 17:00 · Yahoo
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
2026-08-10 20:54 · Yahoo
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
2026-08-04 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.